Meeting
2016 ASCO Annual Meeting
High-dose versus standard-dose rituximab with BEAM in autologous stem cell transplantation (SCT) for relapsed aggressive b-cell non-Hodgkin’s lymphomas (NHL).
Authors
Samer Ali Srour
The University of Texas MD Anderson Cancer Center, Houston, TX
Samer Ali Srour , Issa F. Khouri , Yago Nieto , Uday R. Popat , Muzaffar H. Qazilbash , Paolo Anderlini , Partow Kebriaei , Elizabeth J. Shpall , Richard E. Champlin , Chitra Hosing
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL
Clinical Trial Registration Number
NCT00472056
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7524)
DOI
10.1200/JCO.2016.34.15_suppl.7524
Abstract #
7524
Poster Bd #
80
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Efficacy of radioimmunotherapy-based conditioning with high-dose chemotherapy and autologous stem cell transplantation for transformed lymphoma.
First Author: Amrita Y. Krishnan
Poster
2020 ASCO Virtual Scientific Program
Role of high-dose chemotherapy with autologous stem cell transplantation for primary central nervous system lymphoma: A systematic review.
First Author: Shaha Nabeel
Poster
2011 ASCO Annual Meeting
Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation (ASCT) for Hodgkin lymphoma (HL).
First Author: B. M. William
Poster
2021 ASCO Annual Meeting
Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma.
First Author: Niloufer Khan